Company intelligence / Profile preview

Agis Industries

Ownership: Private
Development stage: Other

Overview

Agis Industries was a leading Israeli generic and specialty pharmaceutical company, with a strong focus on dermatology. It was known for manufacturing both over-the-counter and prescription drugs, with facilities in Israel, the United States, and Germany. The company was acquired by Perrigo in 2005 for approximately $818 million. Publicly available information on clinical results and pipelines is extremely limited, with only one clinical trial (a topical paroxetine hydrochloride ointment for psoriasis) explicitly documented. The company had a reputation for innovation in topical formulations and dermatological products.

Therapeutic areas: Dermatology
Modalities: Small moleculeOintments
Industry: Biotech

Beyond the preview

Go deeper on Agis Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agis Industries.